Is HRT still indicated for the primary prevention of osteoporosis?

References

• Writing group for the PEPI trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 276: 1389–1396
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher J C, Kleerekoper M, Pickar J H. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. J Am Med Assoc 2002; 287: 2668–2676
   PubMed Web of Science ®Google Scholar
• Cauley J A, Robbins J, Chen Z, Cummings S R, Jackson R D, LaCroix A Z, LeBoff M, Lewis C E, McGowan J, Neuner J, Pettinger M, Stefanick M L, Wactawski-Wende J, Watts N B. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative randomized trial. J Am Med Assoc 2003; 290: 1729–1738
   Google Scholar
• Women' Health Initiative Steering Committee. Effects of conjugated estrogen on postmenopausal women with hysterectomy: the Women' Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
   Google Scholar
• Bagger Y Z, Tankó L B, Alexandersen P, Hansen H B, Møllgaard A, Ravn P, Qvist P, Kanis J A, Christiansen C. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004; 34: 728–735
   PubMed Web of Science ®Google Scholar
• Lees B, Stevenson J C. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17-beta and dydrogesterone. Osteoporos Int 2001; 12: 251–258
   PubMed Web of Science ®Google Scholar
• Ettinger B, Ensrud K E, Wallace R, Johnson K C, Cummings S R, Yankov V, Vittinghoff E, Grady D. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004; 104: 443–451
   PubMed Web of Science ®Google Scholar
• Greenwald M W, Gluck O S, Lang E, Rakov V. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause 2005; 12: 741–748
   PubMed Web of Science ®Google Scholar
• Kanis J A, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12: 989–995
   PubMed Web of Science ®Google Scholar
• Singer B R, McLauchlan G J, Robinson C M, Christie J. Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 1998; 80: 243–248
   PubMedGoogle Scholar
• Kanis J A, Johnell O, Oden A, De Laet C, Malstrom D. Epidemiology of osteoporosis and fracture in men. Calcif Tissue Int 2004; 75: 90–99
   PubMed Web of Science ®Google Scholar
• Lamy O, Krieg M A, Burckhardt B, Wasserfallen J B. An economic analysis of hormone replacement therapy for the prevention of fracture in young postmenopausal women. Expert Opin Pharmacother 2003; 4: 1479–1488
   PubMed Web of Science ®Google Scholar
• Cummings S R, Black D M, Thompson D E, Applegate W B, Barrett-Connor E, Musliner T A, Palermo L, Prineas R, Rubin S M, Scott J C, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. J Am Med Assoc 1998; 280: 2077–2082
   PubMed Web of Science ®Google Scholar
• McClung M R, Geusens P, Millar P D, Zippel H, Bensen W G, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333–340
   PubMed Web of Science ®Google Scholar
• Utian W H, Shoupe D, Bachmann G, Pinkerton J H, Pickar J H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065–1079
   PubMed Web of Science ®Google Scholar
• Birkhaeuser M H, Panay N, Archer D F, Barlow D, Burger H, Gambacciani M, Goldstein S, Pinkerton J A, Sturdee D W. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008; 11: 108–123
   PubMed Web of Science ®Google Scholar
• Pines A, David W S, Martin H B, Hermann P GS, Marco G, Nick P. Issued on behalf of the Board of the International Menopause Society. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 181–194
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee D W, Birkhäuser M H, de Villiers T, Naftolin F, Gompel A, Farmer R, Barlow D, Tan D, Maki P, et al. on behalf of the International Menopause Society. HRT in the early menopause: scientific evidence and common perceptions. Climacteric 2008; 11: 267–272
   PubMed Web of Science ®Google Scholar
• Manson J E, Hsia J, Johnson K C, Rossouw J E, Assaf A R, Lasser N L, Trevisan M, Black H R, Heckbert S R, Detrano R, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–534
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer R D, Manson J E, Juller L, Johnson K C, Hendrix S L, Pettinger M, Heckbert S R, Greep N, Crawford S, Eaton C B, Kostis J B, Caralis P, Prentice R, Women's Health Investigators. Conjugated equine estrogens and coronary heart disease. The Women's Health Initiative. Arch Intern Med 2006; 166: 357–365
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson J E, Stampfer M J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 2006; 15: 35–44
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson J E, Colditz G A, Willett W C, Speizer F E, Stampfer M J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933–941
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller L H, Prentice R, Rodabough R J, Psaty B M, Stafford R S, Sidney S, Rosendaal F R. Estrogen plus progestin and risk of venous thrombosis. J Am Med Assoc 2004; 292: 1573–1580
   PubMed Web of Science ®Google Scholar
• Lobo R A. Menopause and stroke and the effects of hormone therapy. Climacteric 2007; 10: 27–31
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Conard J, et al. Hormone therapy and venous thromboembolism among postmenopausal women. Circulation 2007; 115: 840–845
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Chlebowski R T, Hendrix S L, Langer R D, Stefanick M L, Gass M, Lane D, Rodabough R J, Gilligan M A, Cyr M G, Thomson C A, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. J Am Med Assoc 2003; 289: 3243–3253
   PubMed Web of Science ®Google Scholar
• Million Women Study Collaborators. Breast cancer and hormonereplacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
   PubMed Web of Science ®Google Scholar
• Stefanic M L, Anderson G L, Margolis K L, et al. Effects of conjugated equine oestrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647–1657
   PubMed Web of Science ®Google Scholar
• Bush T L, Whiteman M, Flaws J A. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001; 98: 498–508
   PubMed Web of Science ®Google Scholar
• Colditz G A, Hankinson S E, Hunter D J, Willett W C, Manson J E, Stampfer M J, Hennekens C, Rosner B, Speizer F E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–1593
   PubMed Web of Science ®Google Scholar
• Anderson G L, Chlebowski R T, Rossouw J, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006; 55: 103–115
   PubMed Web of Science ®Google Scholar
• Salpeter S R, Walsh J M, Greyber E, Ormiston T M, Salpeter E E. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004; 19: 791–804
   PubMed Web of Science ®Google Scholar
• Jackson R D, Watts N B, Caralis P, Cauley A, Chen Z, Greep N, LaCroix A Z, Lewis C E, Mouton C P, Neuner J M, et al. Fracture risk after estrogen plus progestin discontinuation: the Women's Health Initiative. J Bone Miner Res 2004; S27, [Abstract 1100]
   Google Scholar